Navigation Links
Cardium Reports on Fourth Quarter and Year-End 2009 Financial Results and Recent Developments
Date:3/16/2010

tions.  In January 2009, we submitted a plan of compliance (the "Plan") advising the Exchange of the actions taken or to be taken to regain compliance with the Company Guide.  In February 2009, our Plan was accepted and in July 2009, following completion of the Philips Transaction, we were informed that Cardium was considered to have regained compliance with the Exchange's requirements, in advance of the June 23, 2010 deadline.  On December 28, 2009, the Exchange noted that we were not considered to be in compliance with Section 1003(a)(iv) of the Company Guide because we reported stockholders' equity of less than $4,000,000 and losses from continuing operations and net losses in three of our most recent fiscal years. With losses from continuing operations and net losses in five of our most recent fiscal years, the stockholders' equity threshold would increase to $6,000,000. The Exchange asked us to supplement our previously-filed Plan advising the Exchange of the actions we have taken or will take to regain compliance with the Company Guide by June 23, 2010.  Prior to the January 27, 2010 deadline, we provided a supplement to the Plan to the Exchange.  On March 5, 2010, the Exchange notified the Company that based on its review of information provided, Cardium had made a reasonable demonstration of its ability to regain compliance with the requirements of sections 1003(a)(i) and 1003(a)(ii) of the NYSE AMEX company guide by June 23, 2010.


'/>"/>
SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
4. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
5. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
6. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
7. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
8. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
9. Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
10. Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development
11. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the patented biopharmaceutical, modernized traditional Chinese ... (API) released unaudited preliminary financial results for the ... Fiscal Year 2015 Ended September 30, 2014 Financial ... with $14.7 million in 1Q14 with gross margins ...
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission (ITC) ... (RMD) against BMC Medical. In a notice issued on December ... that ResMed,s patent on its humidifier was invalid. ... "monumental win". "We are very excited with the ITC,s decision ... that we have taken since the very beginning on the ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... SAN DIEGO, March 20, 2012  HUYA Bioscience International ... of China,s preeminent pharmacological researchers, Prof. Deyong Ye ... an international leader in supporting the global development ... Fudan University will focus on specific innovations coming ...
... Mylan Inc. (Nasdaq: MYL ) today ... final approval from the U.S. Food and Drug Administration ... Ibandronate Sodium Tablets, 150mg. This product is the generic ... treatment and prevention of osteoporosis in postmenopausal women. ...
Cached Medicine Technology:HUYA Bioscience Announces New Partnership with a High Profile Pharmaceutical Lab at Shanghai's Prestigious Fudan University 2HUYA Bioscience Announces New Partnership with a High Profile Pharmaceutical Lab at Shanghai's Prestigious Fudan University 3
(Date:12/24/2014)... 24, 2014 Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ... tort litigation currently underway in Pennsylvania’s Philadelphia Court of ... December 24, 2014, court documents indicate that 1,183 claims ... individuals who developed gynecomastia (male breast growth) and other ... Court indicates that this represents an increase of more ...
(Date:12/24/2014)... Dallas, TX (PRWEB) December 24, 2014 ... has announced the expansion of his practice and med-spa ... to the practice’s growing list of cosmetic treatments and ... a solution into the skin,” says Dr. Ho. “As ... aging changes such as wrinkles, sun spots, discolorations or ...
(Date:12/24/2014)... the famous women’s dress supplier, has presented its new selection ... gown promotion. , For those who prefer to ... the collection should be a great choice. The dresses from ... are available with custom service. , Now, all the wedding ... 75% off; most of them come in hot designs. In ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... which is used in the treatment of colon or ... also prescribed to patients who suffer from advanced gastrointestinal ... a multi-kinase inhibitor and it blocks many enzymes which ...
(Date:12/24/2014)... 2014 BambooIndustry.com a famous bamboo flooring ... Today, the company announces its multiple layer bamboo ... on these new products. , Bamboo panel is the ... multiple layer bamboo panel board features high quality selective ... emissions free. The bamboo panel consists of multiple layers ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2
... Homegrown pharma major Panacea Biotec today said it is ... and Japanese encephalitis. // ,"We are currently ... and hepatitis-A. Phase I and II trials for anthrax ... approvals," Panacea Biotec Joint Managing Director Rajesh Jain told ...
... or lesions, that typically precede cervical cancer is much ... human papillomavirus (HPV) than previously reported, according to a ... Biomarkers & Prevention. ,Although doctors have known ... womb can harbor multiple HPV types, this study is ...
... Researchers in the Newcastle University at New South Wales central ... chlamydia and they have received financial// support from the vaccine ... they have developed techniques to immunise animals against the infection. ... researchers are working very hard for the past seven years ...
... U.S. Food and Drug Administration (FDA), along with Publix ... warning against allergen in Publix brand// Chocolate Chip Cookie ... director of media and community relations, "The chocolate ... precaution, we are recalling the product. There have been ...
... A 20-year study of women in the Nurses' Health Study ... open angle glaucoma (POAG), the most common form of glaucoma//, ... study is published in the July issue of the journal ... Infirmary, Brigham and Women's ,Hospital, Harvard School of Public Health ...
... that Statin drugs used to reduce the levels of ... of HDL can cause serious muscle// damage. ... such as Lipitor, Pravachol, Zocor, Crestor and Mevacor to ... damage on patient safety information sheets. ,Statin ...
Cached Medicine News:Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 2Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 3Health News:Type 2 Diabetes Increases the Risk of Glaucoma in Women 2
... laboratories that have decided to change to the ... the RELISA ANAs correlation with IFA and many ... competition. While no ELISA ANA currently on the ... our RELISA ANA screen has been shown to ...
... HEp-2 cell line that has been genetically ... autoantibodies, without affecting the other ANA patterns ... worldwide on the HEp-2000 ANA substrate, which ... used in place of standard HEp-2 cells ...
... ENA assays can be used to ... antibodies, which are associated with various ... lupus erythematosus (Lupus), Sjgren's syndrome, mixed ... scleroderma, polymyositis, dermatomyositis, and Raynaud's phenomenon. ...
... Indirect Fluorescence Assay (IFA) for Anti-native ... for the qualitative and semi-quantitative detection ... nDNA in human serum. Detection of ... be used as an aid in ...
Medicine Products: